| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -57,016 | -48,638 |
| Depreciation | 186 | 125 |
| Equity-based compensation | 4,652 | 3,176 |
| Non-cash interest expense | 1,139 | 253 |
| Amortization of right of use lease asset | 505 | 336 |
| Foreign currency loss (gain) | -381 | -479 |
| Change in fair value of warrants | -7,259 | 2,587 |
| Prepaid expenses and other current assets | 1,611 | 636 |
| Other non-current assets | 895 | 882 |
| Accounts payable | 927 | 877 |
| Lease liability | -557 | -418 |
| Accrued expenses and other current liabilities | -1,823 | -152 |
| Net cash used in operating activities | -61,371 | -42,893 |
| Purchase of property and equipment | 58 | 54 |
| Net cash used in investing activities | -58 | -54 |
| Proceeds from the issuance of debt | 26,434 | 11,720 |
| Payments of debt issuance costs | 251 | 233 |
| Proceeds from issuance of common stock upon exercise of stock options | 2 | - |
| Proceeds from issuance of common stock in connection with at-the-market program, net of issuance costs of 134 | 6,572 | - |
| Net cash provided by financing activities | 32,757 | 11,487 |
| Net decrease in cash, cash equivalents and restricted cash | -28,672 | -31,460 |
| Effect of exchange rate changes on cash | -695 | - |
| Cash and cash equivalents at beginning of period | 60,299 | - |
| Cash and cash equivalents at end of period | 30,932 | - |
IO Biotech, Inc. (IOBT)
IO Biotech, Inc. (IOBT)